Dr. Lal PathLabs Toekomstige groei

Future criteriumcontroles 3/6

Dr. Lal PathLabs zal naar verwachting groeien in winst en omzet met respectievelijk 15.8% en 10.9% per jaar. De winst per aandeel zal naar verwachting groeien met 15.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 22.3% zijn.

Belangrijke informatie

15.9%

Groei van de winst

15.8%

Groei van de winst per aandeel

Healthcare winstgroei	26.2%
Inkomstengroei	10.9%
Toekomstig rendement op eigen vermogen	22.5%
Dekking van analisten	Good
Laatst bijgewerkt	18 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

BSE:539524 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	31,572	5,899	6,609	N/A	16
3/31/2026	28,101	5,096	5,859	N/A	21
3/31/2025	24,967	4,312	5,015	N/A	20
6/30/2024	22,875	3,815	N/A	N/A	N/A
3/31/2024	22,266	3,577	4,779	5,353	N/A
12/31/2023	21,722	3,298	N/A	N/A	N/A
9/30/2023	21,227	3,013	4,767	5,198	N/A
6/30/2023	20,552	2,638	N/A	N/A	N/A
3/31/2023	20,169	2,388	4,115	4,560	N/A
12/31/2022	20,114	2,435	N/A	N/A	N/A
9/30/2022	20,189	2,480	-824	3,884	N/A
6/30/2022	19,835	2,713	N/A	N/A	N/A
3/31/2022	20,874	3,448	-294	4,467	N/A
12/31/2021	20,329	3,669	N/A	N/A	N/A
9/30/2021	19,884	4,041	4,609	5,327	N/A
6/30/2021	19,219	3,944	N/A	N/A	N/A
3/31/2021	15,813	2,916	3,386	3,982	N/A
12/31/2020	14,520	2,407	N/A	N/A	N/A
9/30/2020	13,275	2,003	2,259	2,821	N/A
6/30/2020	12,612	1,955	N/A	N/A	N/A
3/31/2020	13,304	2,259	2,043	2,839	N/A
12/31/2019	13,298	2,405	N/A	N/A	N/A
9/30/2019	12,944	2,322	2,199	2,619	N/A
6/30/2019	12,463	2,086	N/A	N/A	N/A
3/31/2019	12,034	1,992	1,765	2,185	N/A
12/31/2018	11,691	1,923	N/A	N/A	N/A
9/30/2018	11,393	1,825	N/A	N/A	N/A
6/30/2018	10,999	1,761	N/A	N/A	N/A
3/31/2018	10,569	1,707	N/A	1,971	N/A
12/31/2017	10,100	1,617	N/A	N/A	N/A
9/30/2017	9,548	1,565	N/A	N/A	N/A
6/30/2017	9,389	1,586	N/A	N/A	N/A
3/31/2017	9,124	1,546	N/A	1,713	N/A
12/31/2016	8,902	1,576	N/A	N/A	N/A
9/30/2016	8,713	1,876	N/A	N/A	N/A
6/30/2016	8,249	1,413	N/A	N/A	N/A
3/31/2016	7,913	1,322	N/A	1,585	N/A
12/31/2015	7,654	1,201	N/A	N/A	N/A
3/31/2015	6,596	908	N/A	1,218	N/A
3/31/2014	5,579	763	N/A	980	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 539524 ( 15.8% per jaar) ligt boven de spaarquote ( 6.7% ).

Winst versus markt: De winst van 539524 ( 15.8% per jaar) zal naar verwachting langzamer groeien dan de markt Indian ( 17.3% per jaar).

Hoge groeiwinsten: De winst van 539524 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 539524 ( 10.9% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.1% per jaar).

Hoge groei-inkomsten: De omzet van 539524 ( 10.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 539524 zal naar verwachting over 3 jaar hoog zijn ( 22.3 %)

Dr. Lal PathLabs Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.2% to ₹2,794

Price target increased by 8.0% to ₹2,353

Price target increased by 7.2% to ₹2,091

Price target decreased to ₹2,536

Consensus EPS estimates fall by 16%

Price target decreased to ₹2,829

Recent updates

Dr. Lal PathLabs Limited to Report Q2, 2025 Results on Oct 23, 2024

MD & Director recently sold ₹28m worth of stock

Price target increased by 7.2% to ₹2,794

First quarter 2025 earnings: EPS exceeds analyst expectations

Dr. Lal PathLabs Limited Approves Interim Dividend for the Fiscal Year 2024-25

Dr. Lal PathLabs Limited to Report Q1, 2025 Results on Aug 07, 2024

Non Executive Director recently sold ₹14m worth of stock

MD & Director recently sold ₹20m worth of stock

MD & Director recently sold ₹28m worth of stock

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

MD & Director recently sold ₹41m worth of stock

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary

Full year 2023 earnings: EPS and revenues miss analyst expectations

MD & Director recently sold ₹14m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹41m worth of stock

Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million.

Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023

Chief Executive Officer recently sold ₹3.6m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹61m worth of stock

MD & Director recently sold ₹57m worth of stock

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2023 Results on Nov 08, 2022

MD & Director recently sold ₹33m worth of stock

Non Executive Director recently sold ₹2.5m worth of stock

MD & Director recently sold ₹117m worth of stock

Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, Payable on or Before August 26, 2022

First quarter 2023 earnings: EPS misses analyst expectations

Dr. Lal PathLabs Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Non-Executive Director recently sold ₹164m worth of stock

Price target decreased to ₹2,536

Upcoming dividend of ₹6.00 per share